| |
| |
|
| Insider
Information: |
Formela Jean Francois |
| Relationship: |
|
| City: |
Waltham |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
13 |
|
| Direct
Shares |
7,291 |
|
|
Indirect Shares
|
24,762,873 |
|
|
| Direct
Value |
$190,805 |
|
|
|
Indirect Value
|
$273,064,457 |
|
|
| Total
Shares |
24,770,164 |
|
|
| Total
Value |
$273,255,262 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
4
|
|
Stock
price went up :
|
0
|
4
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
4.0
|
| Percentage
Gain/Loss : |
0.0%
|
 179.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Decode Genetics Inc |
DCGN |
Director |
2003-09-09 |
0 |
2003-12-11 |
0 |
Premium* |
|
|
Exelixis Inc |
EXEL |
Director |
2003-11-13 |
0 |
2005-09-07 |
584,519 |
Premium* |
|
|
Nxstage Medical, Inc. |
NXTM |
Director, 10% Owner |
|
0 |
2006-05-26 |
2,592,126 |
Premium* |
|
|
Sgx Pharmaceuticals, Inc. |
SGXP |
Director, 10% Owner |
2006-02-01 |
0 |
2006-02-06 |
2,485,068 |
Premium* |
|
|
Achillion Pharmaceuticals Inc |
ACHN |
Director, 10% Owner |
2006-10-31 |
0 |
2006-10-31 |
1,968,670 |
Premium* |
|
|
Nuvelo Inc |
ABIO |
Director, 10% Owner |
|
0 |
2012-10-22 |
1,579,542 |
Premium* |
|
|
Horizon Pharma, Inc. |
HZNP |
Director, 10% Owner |
|
0 |
2011-08-02 |
5,393,178 |
Premium* |
|
|
Egalet Corp |
EGLT |
Director, 10% Owner |
|
0 |
2014-02-11 |
2,460,949 |
Premium* |
|
|
Intellia Therapeutics, Inc. |
NTLA |
Director |
2022-06-14 |
7,291 |
2021-06-28 |
10,000 |
Premium* |
|
|
Spero Therapeutics Inc |
SPRO |
Director |
2017-11-06 |
0 |
2017-11-06 |
2,408,128 |
Premium* |
|
|
Translate Bio, Inc. |
TBIO |
Director |
2018-07-02 |
0 |
2021-09-14 |
0 |
Premium* |
|
|
Ikena Oncology, Inc. |
IKNA |
Director |
|
0 |
2021-12-14 |
4,143,544 |
Premium* |
|
|
Korro Bio |
KRRO |
|
2023-11-03 |
0 |
2024-04-22 |
1,137,149 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
96 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NXTM |
Nxstage Medical, Inc. |
Director |
– • • |
2005-10-27 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
119,022 |
|
- |
|
| ABIO |
Nuvelo Inc |
Director |
– • • |
2009-01-27 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,402,163 |
|
- |
|
| HZNP |
Horizon Pharma, Inc. |
Director |
– • • |
2011-07-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
326,524 |
|
- |
|
| EGLT |
Egalet Corp |
Director |
– • • |
2014-02-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
308,727 |
|
- |
|
| IKNA |
Ikena Oncology, Inc. |
Director |
– • – |
2021-03-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
169,095 |
|
- |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2021-04-05 |
4 |
AS |
$84.98 |
$67,984 |
I/I |
(800) |
1,112,576 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2021-04-26 |
4 |
AS |
$84.93 |
$68,454 |
I/I |
(806) |
1,111,770 |
0 |
% |
|
| DCGN |
Decode Genetics Inc |
Director |
– • – |
2003-08-20 |
4 |
S |
$2.95 |
$3,835 |
I/I |
(1,300) |
548,641 |
|
- |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2021-06-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,094 |
2,094 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2003-11-20 |
4 |
S |
$6.50 |
$16,250 |
I/I |
(2,500) |
533,850 |
|
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2003-12-05 |
4 |
S |
$6.64 |
$29,230 |
I/I |
(4,400) |
297,292 |
|
- |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2021-04-29 |
4 |
AS |
$85.43 |
$385,546 |
I/I |
(4,513) |
765,101 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2022-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
5,197 |
7,291 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2017-03-10 |
4 |
S |
$14.06 |
$77,410 |
I/I |
(5,504) |
0 |
0 |
- |
|
| IKNA |
Ikena Oncology, Inc. |
Director |
– • – |
2021-12-14 |
4 |
S |
$14.00 |
$83,426 |
I/I |
(5,959) |
1,241,935 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2018-05-16 |
4 |
AS |
$25.04 |
$167,389 |
I/I |
(6,686) |
0 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2018-06-19 |
4 |
AS |
$27.84 |
$186,908 |
I/I |
(6,686) |
0 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
Director |
– • – |
2018-07-16 |
4 |
AS |
$30.97 |
$208,397 |
I/I |
(6,686) |
0 |
0 |
- |
|
| NXTM |
Nxstage Medical, Inc. |
Director |
– • • |
2006-05-26 |
4 |
D |
$10.95 |
$74,405 |
I/I |
(6,795) |
2,592,126 |
|
- |
|
| IKNA |
Ikena Oncology, Inc. |
Director |
– • – |
2021-12-13 |
4 |
S |
$14.64 |
$121,951 |
I/I |
(8,330) |
1,247,894 |
0 |
- |
|
| TBIO |
Translate Bio, Inc. |
Director |
– • – |
2020-08-27 |
4 |
S |
$14.38 |
$145,217 |
I/I |
(10,097) |
3,833,122 |
0 |
% |
|
| NXTM |
Nxstage Medical, Inc. |
Director |
– • • |
2006-05-26 |
4 |
OE |
$7.13 |
$74,394 |
I/I |
10,434 |
2,592,126 |
|
- |
|
| IKNA |
Ikena Oncology, Inc. |
Director |
– • – |
2021-12-10 |
4 |
S |
$15.03 |
$180,195 |
I/I |
(11,989) |
1,256,224 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2003-11-21 |
4 |
S |
$6.36 |
$79,503 |
I/I |
(12,500) |
529,685 |
|
- |
|
| DCGN |
Decode Genetics Inc |
Director |
– • – |
2003-08-26 |
4 |
S |
$3.00 |
$41,100 |
I/I |
(13,700) |
541,791 |
|
- |
|
96 Records found
|
|
Page 1 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
